Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478716 | 0.94 | F2RL3 (0.60) | CYP1A2ALDH1A1CYP2D6LMNACYP3A4 | |
| SCHEMBL13618343 | 0.90 | F2RL3 (0.66) | CYP1A2ALDH1A1CYP2D6LMNACYP3A4 | |
| SCHEMBL27669280 | 0.88 | F2RL3 (0.55) | CYP1A2ALDH1A1CYP2D6LMNACYP3A4 | |
| SCHEMBL3840013 | 0.87 | MAPT (0.57) | CYP1A2ALDH1A1CYP2D6LMNACYP3A4 | |
| SCHEMBL4478119 | 0.86 | CNR2 (0.59) | CYP1A2ALDH1A1CYP2D6LMNACYP3A4 | |
| SCHEMBL3843948 | 0.83 | F2RL3 (0.53) | ALDH1A1LMNAHTTNPSR1F2RL3 | |
| SCHEMBL4480794 | 0.83 | RORC (0.54) | ALDH1A1LMNAHTTNPSR1F2RL3 | |
| SCHEMBL4476028 | 0.80 | CHRM1 (0.50) | ALDH1A1LMNAHTTF2RL3PDE5A | |
| SCHEMBL3621787 | 0.79 | ALDH1A1 (0.67) | CYP1A2ALDH1A1CYP2D6LMNACYP3A4 | |
| SCHEMBL17516325 | 0.78 | GLS (0.57) | CYP1A2ALDH1A1CYP2D6LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425011-B1 | ENHANCEMENT OF LEARNING AND MEMORY AND TREATMENT OF AMNESIA | CARLSBAD TECHNOLOGY INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7514465-B2 | Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2009-04-07 | — | — | US | disclosed |
| EP-1331223-B1 | Method of treating sepsis | YUNG SHIN PHARMACEUTICAL IND (TW) | 2008-02-13 | — | — | EP | disclosed |
| EP-1659115-A1 | Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents | Yung Shin Pharm. Ind. Co., Ltd. (TW) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | FLT4, FLT1, KDR | CYP1A2 1288/4885ALDH1A1 851/4885CYP2D6 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.